Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Alexis Ogdie¹, Mei Liu ², Meghan Glynn ³, Kelechi Emeanuru ², Leslie Harrold ⁴, Sven Richter ⁵, Benoit Guerette ⁵ and Philip Mease ⁶, ¹Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, ⁵Celgene Corporation, Summit, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Disease Activity and comorbidity, PRO, Psoriatic arthritis, registry

Session Information

Date: Tuesday, November 12, 2019

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Oligoarticular PsA accounts for ≈50% of PsA worldwide, but only a paucity of data describes disease burden among these patients. The Corrona PsA/SpA Registry, a prospective, US-based, observational cohort study, collects real-world data on PsA patient characteristics and treatment, including oligoarthritis. This analysis characterized patient demographics, clinical characteristics, and patient-reported outcomes (PROs) at treatment initiation in the Corrona PsA/SpA Registry in biologic-naïve patients with oligoarticular (≤4 swollen and ≤4 tender joints) vs polyarticular ( >4 swollen or >4 tender joints) PsA.

Methods: Biologic-naïve patients ≥18 years of age diagnosed with PsA and enrolled in the registry who initiated apremilast, biologics, and/or csDMARDs for PsA from March 2013‒December 2018 were included. Patient demographics, disease activity, treatment history, comorbidities, and PRO data were analyzed at treatment initiation; comparisons between oligoarticular and polyarticular PsA patients were performed using t-tests or Wilcoxon rank-sum tests for continuous variables and chi-square tests or Fisher’s exact tests for categorical variables.

Results: 330 biologic-naïve PsA patients initiating apremilast, biologics, and/or csDMARDs were included (oligoarthritis: n=149; polyarthritis: n=181). Demographics and clinical characteristics were mostly similar for patients with oligoarthritis and polyarthritis, including mean age (51.6 vs 54.3 years; P=0.068), proportion of females (51.0% vs 59.7%; P=0.117), mean disease duration (3.0 vs 3.1 years; P=0.789), and prior use of csDMARDs (13.4% vs 21.0%; P=0.072). Comorbidity history was similar between the 2 groups, but the proportion of patients with fibromyalgia was higher in the polyarthritis group (2.0% vs 8.8%; P=0.008; Table 1). Patients with oligoarthritis had lower disease activity at treatment initiation vs those with polyarthritis based on SJC (0-66) and TJC (0-68), nail psoriasis VAS score, cDAPSA score, presence of enthesitis, SPARCC enthesitis score, presence of dactylitis, and dactylitis count. More patients with oligoarthritis were classified with minimal disease activity vs patients with polyarthritis (Table 2). Mean Pain VAS (42.6 vs 59.8), Fatigue VAS (41.9 vs 55.3), Patient’s Global Assessment of Disease Activity VAS (38.6 vs 47.7), and HAQ-DI (0.7 vs 1.0) scores were significantly lower and the proportion of patients with HAQ-DI score < 0.5 was significantly greater for patients with oligoarthritis vs polyarthritis (39.7% vs 20.1%) (all P≤0.001). Presence of inflammatory back pain (8.7% vs 10.5%; P=0.588) and mean psoriasis-involved body surface area (8.0% vs 6.8%; P=0.276) were similar in the 2 groups.

Conclusion: This Corrona PsA/SpA Registry analysis showed similar overall disease and comorbidity burden in biologic-naïve patients with oligoarthritis and polyarthritis. However, patients with oligoarthritis vs polyarthritis had lower scores on disease activity and PRO measures at treatment initiation.

Disclosure: A. Ogdie, AbbVie, 5, 8, Abbvie, 5, 8, AbbVie, BMS, Eli Lilly, Novartis, Pfizer, Takeda, 5, Amgen, 2, 4, 5, 8, Amgen to Forward National Databank, 2, BMS, 5, Bristol-Myers Squibb, 5, Celgene, 4, 5, 8, Corrona, 5, CORRONA, 5, From Noavrtis to husband, 7, Lilly, 5, Lily, 5, Novartis, 2, 5, 7, Novartis to UPenn, 2, Novartis, Pfizer, 2, Pfizer, 2, 5, Pfizer Inc, 2, 5, Pfizer to UPenn, 2; M. Liu, Corrona, LLC, 3; M. Glynn, Corrona, LLC, 3; K. Emeanuru, Corrona, LLC, 3; L. Harrold, Abbvie, 5, AbbVie, Inc., 5, Bristol-Myers Squibb, 5, Corrona, LLC, 1, 3, Genentech, 5, Pfizer, 2; S. Richter, Celgene Corporation, 3; B. Guerette, Celgene Corporation, 3; P. Mease, Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Genentech, Janssen, Novartis, Pfizer, Roche, UCB, 2, 5, Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB, 8, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, Abbvie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 5, Abbvie, Amgen, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, UCB, 8, Abbvie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 2, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Leo, Merck, Novartis, Pfizer and UCB., 5, 8, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Leo, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharmaceutical Industries, Inc., and UCB, 2, Abbvie, Amgen, Brsitol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 5, Abbvie, Amgen, Brsitol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, UCB, 8, Abbvie, Amgen, Brsitol Myers Squibb,Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB, 2, Amgen, 2, 5, 6, 8, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, GSK, Janssen, Leo, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharmaceutical Industries, and UCB, 5, BMS, 2, 5, 8, Boehringer Ingelheim, 2, 5, Boerhinger Ingelheim, 5, Bristol Myers Squibb, 2, 5, 8, Bristol Myers Squibb Co., 2, 5, 8, Bristol-Myers Squibb, 2, 5, 6, 8, Celgene, 2, 5, 6, 8, Celgene Corp., 2, 5, 8, CORRONA, 5, Eli Lilly, 2, 5, 8, Galapagos, 2, 5, 8, Genentech, 2, 5, 6, 8, Gilead, 2, 5, 8, Janssen, 2, 5, 6, 8, Janssen Inc, 2, 5, 8, Leo, 2, 5, 8, Lilly, 2, 5, 6, 8, Merck, 2, 5, 8, Novartis, 2, 5, 6, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, 6, Sun, 2, 5, SUN, 2, 5, Sun Pharma, 2, 5, Sun Pharmaceutical Industries, 2, 5, Sun Pharmaceutical Industries, Inc., 2, 5, 8, UCB, 2, 5, 6, 8, UCB Pharma, 2, 5, 8.

To cite this abstract in AMA style:

Ogdie A, Liu M, Glynn M, Emeanuru K, Harrold L, Richter S, Guerette B, Mease P. Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/burden-of-disease-at-treatment-initiation-among-biologic-naive-patients-with-oligoarticular-versus-polyarticular-psoriatic-arthritis-in-the-corrona-psoriatic-arthritis-spondyloarthritis-registry/. Accessed April 16, 2021.

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/burden-of-disease-at-treatment-initiation-among-biologic-naive-patients-with-oligoarticular-versus-polyarticular-psoriatic-arthritis-in-the-corrona-psoriatic-arthritis-spondyloarthritis-registry/